Company News

bioMérieux co-hosted a conference with the Embassy of France in the United States on May 14 titled, “Rising to the Challenge: United Against Antimicrobial Resistance.” The conference featured renowned speakers from various sectors, including government agencies, academia, and industry, who discussed the latest global policies and initiatives to tackle antimicrobial resistance (AMR). His Excellency Laurent Bili, French Ambassador to the United States and Alexandre Mérieux, bioMérieux Chairman of the Board of Directors, gave opening remarks.

bioMérieux, a world leader in the field of in vitro diagnostics, has received the 2024 Business of the Year Award, presented by the Utah Governor’s Office of Economic Opportunity at One Utah Summit April 11-12, in Salt Lake City.

bioMérieux has entered into a strategic research collaboration with the US Food and Drug Administration (FDA), Center for Food Safety and Applied Nutrition (CFSAN), Offices of Applied Research and Safety Assessment (OARSA) and Regulatory Science (ORS) to develop tools to combat food-borne pathogens.

A strategic R&D partnership between bioMérieux and the University of Pittsburgh (Pitt) has been launched, paving the way for many innovative and collaborative research projects.

CATTI, Canadian Advanced Therapies Training Institute, and bioMérieux Canada are combining their respective strengths to enhance the training of the workforce in advanced therapies and the production of quality control solutions (for the pharmaceutical industries).